doxorubicin

Type: Keyphrase

Name: doxorubicin

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Smaller Companies With Potential For Big Returns

During a bull market many investors often comb through the underachievers looking for companies that are full of potential, exhibit steady growth or have terrific fundamentals. The following four small companies have some of these elements and offer terrific ... [Published Seeking Alpha - May 16 2013]

Entities: Neuralstem Inc, Amyotrophic Lateral Sclerosis, Stocks, Cetrotide, perifosine

First reported May 16 2013 - Updated May 16 2013 - 3 reports

MultiCell Technologies Files U.S. Patent Application for Targeted Delivery of Noncoding Micro RNAs for the Treatment of Liver Cancer

WOONSOCKET, R.I.Hepatocellular carcinoma is the most common form of primary liver cancer, and is a leading cause of cancer death. Hepatocellular carcinoma remains an unmet medical need, and today's approaches for treatment are of limited efficacy. A potential ... [Published Bio-Medicine - May 16 2013]

Entities: Multicell Technologies Inc, Liver Cancer, hepatocellular carcinoma, Tumor, doxorubicin

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Researchers Submit Patent Application, "Lipid Bilayer Carrie. . .

Researchers Submit Patent Application, "Lipid Bilayer Carrier for Drugs Or Imaging Agents", for ApprovalKoninklijke Philips Electronics N.v.NewsRx.comBy a News Reporter-Staff News Editor at Biotech Week -- From Washington, D.C., NewsRx journalists report ... [Published Equities.com - May 15 2013]

Entities: Liposome, Carbon, Drugs, Lipid

First reported May 14 2013 - Updated May 15 2013 - 1 reports

Thomas Jefferson University

Researchers from Thomas Jefferson University Provide Details of New Studies and Findings in the Area of Doxorubicin Therapy

By a News Reporter-Staff News Editor at Biotech Week -- Data detailed on Drugs and Therapies have been presented. According to news reporting out of Philadelphia, Pennsylvania, by NewsRx editors, research stated, "Triple-negative breast cancer (TNBC) ... [Published HighBeam Research - May 14 2013]

Entities: Thomas Jefferson University, doxorubicin, Biotechnology, Breast Cancer

First reported May 15 2013 - Updated May 15 2013 - 1 reports

A Novel Manganese Complex, Mn-(II) N-(2-Hydroxy Acetophenone) Glycinate overcomes Multidrug-Resistance in Cancer

Author(s): Ruma Dey Ghosh , Kaushik Banerjee , Satyajit Das , Avishek Ganguly , Paramita Chakraborty , Avijit Sarkar , Mitali Chatterjee , Soumitra K ChoudhuriMultidrug resistance (MDR) remains a significant problem for effective cancer chemotherapy. ... [Published Bionity.com - May 15 2013]

Entities: Acetophenone, Glycine, Manganese, Cancer

First reported May 14 2013 - Updated May 14 2013 - 1 reports

Survey: Drug Shortages May Weaken Cancer Care

Shortages of cancer drugs continue to take a toll on patient care, increasing drug errors and costs, and leading in some cases to the purchase of short-supply products from “gray-market” suppliers, according to results of a new survey of oncology pra ... [Published Pharmacy Practice News - May 14 2013]

Entities: Drugs, doxorubicin, Cancer, leucovorin, liposomal

First reported May 13 2013 - Updated May 13 2013 - 1 reports

Ergomed joins Aeterna Zentaris for Phase III cancer trial

QUEBEC CITY announced in early April the establishment of a co-development and profit-sharing agreement with for AEZS-108 in endometrial cancer. Ergomed was chosen to conduct the upcoming multi-center Phase III trial of AEZS-108 in endometrial cancer. ... [Published Drug Discovery News - May 13 2013]

Entities: AEterna Zentaris Inc, Phase III, Endometrial Cancer

First reported May 13 2013 - Updated May 13 2013 - 1 reports

Team Develops MRI Contrast Agent for Cancer Diagnosis, Treatment

Domestic researchers have developed a contrast agent which can diagnose and treat cancer simultaneously during magnetic resonance imaging (MRI) scans.A team led by Professor Lee Kwang-ryeol at Korea University on Monday said that the researchers developed ... [Published Korea Broadcasting System - May 13 2013]

Entities: Magnetic Resonance Imaging, Cancer, Korea University, doxorubicin

First reported May 09 2013 - Updated May 09 2013 - 5 reports

Celsion's Q1 Call: What You Need To Know

Introduction and Q1 EarningsI've been covering Celsion (CLSN) since the beginning of January 2012, when it was anticipating its Phase III results for ThermoDox with RFA (radio frequency ablation).ThermoDox is a unique liposomal delivery method of getting ... [Published Seeking Alpha - May 09 2013]

Entities: Celsion Corporation, ThermoDox, liposomal, Phase III

First reported May 06 2013 - Updated May 07 2013 - 5 reports

3 Healthcare Stock Stories For Monday Investment Wellness

Celgene Corporation ( NASDAQ: CELG ): Closing price $121.22Celgene Corporation’s subsidiary Celgene International Sàrl, announced Monday that statistical significance was attained for the primary endpoint of ACR 20 at week 16 for patients receiving apremilast 20 ... [Published Wall St. Cheat Sheet - May 07 2013]

Entities: doxorubicin, Phase IIb, Celgene Corporation

First reported May 01 2013 - Updated May 02 2013 - 3 reports

Study shows efficacy of PEGylated liposomal doxorubicin in intracranial model of breast cancer

Breast cancer brain metastases present a challenge to clinicians because there are few systemic therapies capable of crossing the blood-brain barrier to control the disease. An international team, led by scientists at the University of North Carolina ... [Published News-Medical.Net - May 02 2013]

Entities: doxorubicin, PEGylation, liposomal

First reported Apr 30 2013 - Updated May 01 2013 - 6 reports

DELCATH SYSTEMS, INC.: Delcath to report first quarter 2013 results on may 8, 2013

Company to Provide Update on ODAC Panel MeetingQUEENSBURY,NY-May 1,2013 - Delcath Systems, Inc. (NASDAQ: DCTH) today announced that it will host a conference call and webcast on Wednesday, May 8, 2013 at 4:30 p.m. ET to discuss the Company's financial ... [Published 4 Traders - May 01 2013]

Entities: melphalan, Delcath Systems Incorporated, FDA Food & Drug Administration, hepatic, doxorubicin

Quotes

More From BioPortfolio on "Liposomes Expand Cancer Drug's Bioavailability and Potency in Mouse Model"

Liposomes Expand Cancer Drug's Bioavailability and Potency in Mouse Model [Published BioPortfolio - May 16 2013]

"In a still further aspect, the invention relates to any of the foregoing carriers for use in the in vivo release of a substance contained therein, respectively to treatment and imaging methods comprising administering any of the foregoing carriers to an animal, preferably a human, and affecting the in vivo release of a substance contained therein."

Researchers Submit Patent Application, "Lipid Bilayer Carrie. . . [Published Equities.com - May 15 2013]

...According to news reporting out of Philadelphia, Pennsylvania, by NewsRx editors, research stated, "Triple-negative breast cancer (TNBC) is an aggressive disease that lacks established ... (Publication: Biotech Week)"

Researchers from Thomas Jefferson University Provide Details of New Studies and Findings in the A ... [Published HighBeam Research - May 14 2013]

...and exploring acquisition opportunities," said Michael Tardugno, Celsion's President and Chief Executive Officer, in a release dated May 9. "At this point, we have concluded that emerging findings from our post hoc analysis of the Heat Study provide a basis for review with various regulatory agencies and an opportunity to discuss a path forward for our HCC development program. Our recent expense reduction initiatives ensure a strong balance sheet as we explore opportunities to broaden our product pipeline and mitigate risk."

Celsion Reports 1Q 2013 Financial Results [Published Individual.com - May 14 2013]

More Content

sort by: Date \| Relevance
Liposomes Expand Cancer Drug's Bioavailability ... [Published Biotech Daily - May 16 2013]
Liposomes Expand Cancer Drug's Bioavailability ... [Published BioPortfolio - May 16 2013]
Smaller Companies With Potential For Big Returns [Published Seeking Alpha - May 16 2013]
MultiCell Technologies Files U.S. Patent Applic... [Published Bio-Medicine - May 16 2013]
MultiCell Technologies Files U.S. Patent Applic... [Published Michigan Live - May 16 2013]
MultiCell Technologies Files U.S. Patent Applic... [Published KSWT13 - May 16 2013]
MOLECULAR MEDICINE SPA: MolMed clinical develop... [Published 4 Traders - May 16 2013]
Researchers Submit Patent Application, "Lipid B... [Published Equities.com - May 15 2013]
Amarin & Celsion: Post-Earnings Roundup [Published Seeking Alpha - May 15 2013]
‘I wanted to raise children and die when I’m 10... [Published Irish Examiner - May 15 2013]
A Novel Manganese Complex, Mn-(II) N-(2-Hydroxy... [Published Bionity.com - May 15 2013]
Researchers from Thomas Jefferson University Pr... [Published HighBeam Research - May 14 2013]
Induced pluripotent stem cells in high-throughp... [Published Drug Discovery World - May 14 2013]
Celsion Reports 1Q 2013 Financial Results [Published Individual.com - May 14 2013]
Survey: Drug Shortages May Weaken Cancer Care [Published Pharmacy Practice News - May 14 2013]
Ergomed joins Aeterna Zentaris for Phase III ca... [Published Drug Discovery News - May 13 2013]
Anticipatory and Delayed Nausea Remain Concerns... [Published OncLive - May 13 2013]
Team Develops MRI Contrast Agent for Cancer Dia... [Published Korea Broadcasting System - May 13 2013]
Oasmia Pharmaceutical AB (OASM) - Pharmaceutica... [Published TransWorldNews - May 10 2013]
Lilly Announces Enzastaurin Phase III Study Did... [Published Bio-Medicine - May 10 2013]
Lilly Announces Enzastaurin Phase III Study Did... [Published State Journal - May 10 2013]
Actavis Confirms District Court Ruling In Gener... [Published BioMedReports - May 10 2013]
Immunomedics' CEO Discusses F3Q13 Results - Ear... [Published Seeking Alpha - May 09 2013]
Subnanometer Local Temperature Probing and Remo... [Published Nano Letters - May 09 2013]
Salt-Induced Stability and Serum-Resistance of ... [Published Biomacromolecules - May 09 2013]
Celsion's Q1 Call: What You Need To Know [Published Seeking Alpha - May 09 2013]
Celsion Corporation Reports First Quarter 2013 ... [Published BioSpace - May 09 2013]
Celsion: New Findings Show Act Of Desperation [Published Seeking Alpha - May 09 2013]
Celsion Corporation Reports First Quarter 2013 ... [Published Yahoo! Finance - May 09 2013]
Celsion Corporation Reports First Quarter 2013 ... [Published NewsBlaze - May 09 2013]

sort by: Date \| Relevance
BioAlliance Pharma’s Sitavig® Receives Market A... [Published Business Wire - Apr 15 2013]
EGEN, Inc. Announces a Phase I Clinical Trial f... [Published PR Newswire: Health - Mar 19 2013]
CytRx Announces Positive Results from Animal Tr... [Published EON Health & Medicine - Jan 28 2013]
CytRx Announces Positive Results from Animal Tr... [Published Business Wire Science: Science News - Jan 28 2013]
CytRx Announces Positive Results from Animal Tr... [Published Business Wire Health News - Jan 28 2013]